X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (138) 138
hematology (129) 129
female (106) 106
middle aged (105) 105
adult (104) 104
male (104) 104
transplantation (90) 90
index medicus (83) 83
aged (67) 67
adolescent (52) 52
immunology (50) 50
transplantation, homologous (46) 46
stem cells (45) 45
article (44) 44
hematology, oncology and palliative medicine (41) 41
treatment outcome (41) 41
experimental results (38) 38
p p: colliding beams (37) 37
p p: scattering (36) 36
cern lhc coll (35) 35
lhc-b (35) 35
chemotherapy (32) 32
hematopoietic stem cell transplantation (32) 32
bone-marrow-transplantation (30) 30
recurrence (30) 30
disease-free survival (29) 29
retrospective studies (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
cancer (26) 26
colony-stimulating factor (26) 26
survival rate (26) 26
young adult (26) 26
oncology (25) 25
stem-cell transplantation (25) 25
7000 gev-cms8000 gev-cms (24) 24
follow-up studies (24) 24
therapy (23) 23
transplantation conditioning - methods (23) 23
filgrastim (22) 22
hematopoietic stem cell transplantation - methods (21) 21
hematopoietic stem cells (21) 21
particle physics (21) 21
child (20) 20
stem cell transplantation (20) 20
transplantation, autologous (20) 20
colliding beams [p p] (19) 19
experiment (19) 19
lymphomas (19) 19
transplantation conditioning (19) 19
versus-host-disease (19) 19
vidarabine - analogs & derivatives (19) 19
bone marrow (18) 18
care and treatment (18) 18
hematopoietic stem cell transplantation - adverse effects (18) 18
physics - high energy physics - experiment (18) 18
scattering [p p] (18) 18
bone-marrow (17) 17
combined modality therapy (17) 17
disease (17) 17
leukemia (17) 17
risk factors (17) 17
statistical (17) 17
survival analysis (17) 17
blood (16) 16
graft vs host disease - etiology (16) 16
graft vs host disease - prevention & control (16) 16
high-dose chemotherapy (16) 16
lymphoma (16) 16
bone marrow transplantation (15) 15
bone-marrow transplantation (15) 15
g-csf (15) 15
hodgkin disease - therapy (15) 15
prognosis (15) 15
recombinant proteins (15) 15
relapse (15) 15
survival (15) 15
vidarabine - administration & dosage (15) 15
acute myeloid-leukemia (14) 14
analysis (14) 14
hemic and lymphatic diseases (14) 14
high energy physics - experiment (14) 14
melphalan (14) 14
melphalan - administration & dosage (14) 14
abridged index medicus (13) 13
busulfan (13) 13
granulocyte colony-stimulating factor - administration & dosage (13) 13
granulocyte colony-stimulating factor - pharmacology (13) 13
remission induction (13) 13
acute disease (12) 12
allogeneic transplantation (12) 12
cp: violation (12) 12
graft vs host disease - mortality (12) 12
mortality (12) 12
patient outcomes (12) 12
physics (12) 12
rituximab (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
fludarabine (11) 11
granulocyte colony-stimulating factor - adverse effects (11) 11
muon: pair production (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 16, pp. 1487 - 1496
Journal Article
Blood, ISSN 0006-4971, 10/2009, Volume 114, Issue 18, pp. 3721 - 3722
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2017, Volume 178, Issue 4, pp. 561 - 570
Summary High‐dose rituximab (HD‐R) combined with carmustine, cytarabine, etoposide and melphalan (BEAM) and autologous stem cell transplant (ASCT) was... 
non‐Hodgkin lymphoma | carmustine, cytarabine, etoposide and melphalan | rituximab | autologous transplant | non-Hodgkin lymphoma | cytarabine | MANTLE CELL | CHEMOTHERAPY | carmustine | TRIAL | etoposide and melphalan | IMPACT | THERAPY | INDOLENT LYMPHOMA | IMPROVES | HEMATOLOGY | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Dose-Response Relationship, Drug | Young Adult | Melphalan - adverse effects | Neoplasms, Second Primary | Adult | Female | Child | Carmustine - adverse effects | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Graft Survival | Treatment Outcome | Cytarabine - administration & dosage | Rituximab - administration & dosage | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Aged | Carmustine - administration & dosage | Etoposide | Dosage and administration | Analysis | Standards | Stem cells | Autografts | Statistical analysis | Transplants & implants | Adaptive algorithms | Stem cell transplantation | Rituximab | Transplantation | Patients | Survival | Lymphoma | Confidence intervals | Demographics | Randomization | Cytarabine | Salvage | Lymphocytes B | Melphalan | Remission | Health risk assessment | Bayesian analysis | Non-Hodgkin’s lymphoma | BEAM | NHLs
Journal Article
Blood, ISSN 0006-4971, 11/2001, Volume 98, Issue 10, pp. 2900 - 2908
Hematopoietic stem cells from 4 different sources have been or are being used for the reconstitution of lymphohematopoietic function after myeloablative,... 
ALLOGENEIC BLOOD | PROGENITOR CELLS | CYTOKINE PRODUCTION | COLONY-STIMULATING FACTOR | IMMUNE RECONSTITUTION | TELOMERASE ACTIVITY | NORMAL DONORS | FOLLOW-UP | HEMATOLOGY | VERSUS-HOST DISEASE | RANDOMIZED TRIAL | T-Lymphocyte Subsets - immunology | Neutrophils - cytology | Graft vs Host Disease - epidemiology | Follow-Up Studies | Humans | Hematopoietic Stem Cell Transplantation - mortality | Liver - embryology | Filgrastim | Transplantation, Homologous | Multicenter Studies as Topic | Hematopoietic Stem Cell Transplantation - adverse effects | Registries | Leukocyte Count | Retrospective Studies | Monocytes - physiology | Graft vs Host Disease - etiology | Granulocyte Colony-Stimulating Factor - adverse effects | Blood Cells - transplantation | Lymphocyte Activation | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Graft Survival | Immunophenotyping | Fetal Blood - cytology | Recombinant Proteins - pharmacology | Organ Specificity | Randomized Controlled Trials as Topic | Monocytes - drug effects | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Platelet Count | Bone Marrow Transplantation - mortality | Tissue and Organ Procurement - methods | Bone Marrow Transplantation - adverse effects | Liver - cytology | Hematopoietic Stem Cell Mobilization - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Chronic Disease | Hematopoietic Stem Cells
Journal Article
Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 10, pp. 2304 - 2311
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or... 
Transplants & implants | Clinical trials | Stem cell transplantation | Transplantation | Cytarabine | Melphalan | Remission | Conditioning | Medical research | Autografts | Cell survival | Etoposide | Rituximab | Patients | Survival | Lymphoma | Yttrium isotopes | Chemotherapy | Lymphocytes B | Experimental design | Stem cells | Lymphomas | Yttrium | Cancer | B-cell lymphoma
Journal Article
Haematologica, ISSN 0390-6078, 07/2010, Volume 95, Issue 7, pp. 1183 - 1190
Journal Article
Mycopathologia, ISSN 0301-486X, 12/2014, Volume 178, Issue 5, pp. 465 - 470
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2017, Volume 177, Issue 4, pp. 567 - 577
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5530 - 5536
Journal Article
Advances in Hematology, ISSN 1687-9104, 11/2011, Volume 2011, pp. 601953 - 8
Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess of 90%. We sought to identify a... 
Clinical Study
Journal Article